2025年欧洲肿瘤内科学会（ESMO）年会即将于10月17-21日在德国柏林盛大开幕。作为肿瘤学界的盛会，本次会议广泛覆盖了从基础到临床的前沿研究，为医疗专业人士提供了一个交流最新发现和多学科讨论的学术平台。
日前，ESMO官方网站已公布了LBA（Late-Breaking Abstract）摘要标题，【肿瘤资讯】特此整理。
优选论文专场——早期乳腺癌
Proffered Paper session - Breast cancer, early stage
专场时间：2025年10月17日14:00 - 15:30（本文时间均为德国时间，比北京时间晚6个小时）
专场地点：Munich Auditorium - CityCube B
摘要号：LBA12
POSITIVE研究（内分泌反应性乳腺癌女性中断治疗的妊娠结局和安全性）的5年随访结果
5-Year Follow-up Results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial
讲者：Olivia Pagani (Rennaz, Switzerland)
摘要号：LBA13
monarchE研究：辅助阿贝西利联合内分泌治疗用于HR+、HER2-高危早期乳腺癌的主要总生存期（OS）结果
monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC)
讲者：Stephen R. Johnston (London, United Kingdom)
摘要号：LBA14
NATALEE研究5年结果：辅助瑞波西利联合非甾体类芳香化酶抑制剂治疗HR+/HER2-早期乳腺癌患者
Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes
讲者：John P. Crown (Dublin, Ireland)
摘要号：LBA15
低剂量帕博利珠单抗联合蒽环类和紫杉类新辅助化疗治疗三阴性乳腺癌：一项随机对照试验
Low Dose Pembrolizumab in Addition to Neoadjuvant Anthracycline and Taxane in Triple Negative Breast Cancer: A Randomized Controlled Trial
讲者：Atul Batra (New Delhi, India)
优选论文专场1——转移性乳腺癌
Proffered paper session 1 - Breast cancer, metastatic
专场时间：2025年10月18日10:15 - 11:45
专场地点：Berlin Auditorium - Hub 27
摘要号：LBA17
VIKTORIA-1研究：在HR+/HER2-/PIK3CA野生型(WT)晚期乳腺癌患者中，Gedatolisib联合氟维司群± 哌柏西利对比氟维司群的首次研究结果
Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
讲者：Sara A. Hurvitz (Seattle, United States of America, CA)
摘要号：LBA23
芦康沙妥珠单抗（sac-TMT）对比研究者选择的化疗（ICC）治疗既往接受过治疗的局部晚期或转移性HR+/HER2-乳腺癌：随机、多中心Ⅲ期 OptiTROP-Breast02 研究的结果
Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): results from the randomized, multi-center phase 3 OptiTROP-Breast02 study
讲者：樊英 (北京, 中国)
摘要号：LBA24
在 HER2 阳性不可切除或转移性乳腺癌中，比较Trastuzumab botidotin与恩美曲妥珠单抗（T-DM1）的疗效：一项随机Ⅲ期研究的结果
Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: results from a randomized phase 3 study
讲者：胡夕春(上海, 中国)
优选论文专场2——转移性乳腺癌
Proffered paper session 2 - Breast cancer, metastatic
专场时间：2025年10月19日8:30 - 10:00
专场地点：Munich Auditorium - CityCube B
摘要号：LBA18
德曲妥珠单抗（T-DXd）+ 帕妥珠单抗（P）vs 紫杉类+曲妥珠单抗+帕妥珠单抗（THP）用于HER2+ 晚期/转移性乳腺癌患者的疗效：DESTINY-Breast09 研究关键亚组的额外分析
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): additional analyses of DESTINY-Breast09 in key subgroups of interest
讲者：Sibylle Loibl (Neu-Isenburg, Germany)
摘要号：LBA19
SHR-A1811 对比吡咯替尼联合卡培他滨治疗HER2+晚期/转移性乳腺癌：一项多中心、开放标签、随机、3 期研究（HORIZON-Breast01）
SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): a multicenter, open-label, randomized, phase 3 study (HORIZON-Breast01)
讲者：宋尔卫 (Guangzhou, China)
摘要号：LBA20
ASCENT-03 研究的主要结果：一项关于戈沙妥珠单抗对比化疗治疗既往未接受过治疗且无法接受 PD-(L) 1 抑制剂的晚期三阴性乳腺癌患者的随机 3 期研究
Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
讲者：Javier C. Cortés (Barcelona, Spain)
简短口头报告专场——转移性乳腺癌
Mini oral session - Breast cancer, metastatic
专场时间：2025年10月20日10:15 - 11:45
专场地点：Munich Auditorium - CityCube B
摘要号：LBA22
ASCENT-04/KEYNOTE-D19研究：戈沙妥珠单抗+帕博利珠单抗 vs 化疗+帕博利珠单抗治疗既往未接受过治疗的 PD-L1+ 转移性三阴性乳腺癌（mTNBC）的患者报告结局（PROs）
Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase 3 ASCENT-04/KEYNOTE-D19 study
讲者：Evandro De Azambuja (Brussels, Belgium)
摘要号：LBA25
Culmerciclib 联合氟维司群作为HR+/HER2- 晚期乳腺癌的一线治疗：一项Ⅲ期试验（CULMINATE-2）
Culmerciclib Plus Fulvestrant as First-Line Treatment for HR+/HER2- Advanced Breast Cancer: A Phase 3 Trial (CULMINATE-2)
讲者：宋尔卫 (广州, 中国)
摘要号：LBA26
LY4064809（STX-478），一种泛突变选择性 PI3Kα 抑制剂的Ⅰ/Ⅱ期试验：PIKALO-1 研究的更新结果
A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor: Updated PIKALO-1 results
讲者：Dejan Juric (Boston, United States of America, MA)
https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session
排版编辑：肿瘤资讯-Jina
苏公网安备32059002004080号
